
|Videos|November 16, 2022
Managing Adverse Events of Lenvatinib in Patients with RAI-R-DTC
Author(s)Lori J. Wirth, MD
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
5


































